



28 January 2021

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Exercise of Options and Total Voting Rights

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 16,666 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options under the Company's Third Unapproved Share Option scheme by certain option holders.

Application has been made to the London Stock Exchange for the 16,666 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 February 2021.

After Admission, the total number of Ordinary Shares in issue will be 180,017,154 and the total number of voting rights will therefore be 180,017,154. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.

Contacts:

Omega Diagnostics Group PLC

Colin King, Chief Executive
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030
www.omegadiagnostics.com

finnCap Ltd

Geoff Nash / Teddy Whiley (Corporate Finance)
Alice Lane (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or
omega@walbrookpr.com
Mob: 07980 541 893
Mob: 07584 391 303